/daily ·06 JUL 2026 ·MONDAY ·2 MIN READ ·5 STORIES

Centenarian chemistry, sleeping circuits, and reprogrammed eyes

A distinctive metabolite fingerprint in centenarian blood, a newly mapped sleep-to-growth-hormone neural circuit, the first human trial of epigenetic reprogramming for age-related blindness, and two Nature Aging papers on telomere repair and motor neuron protection in ALS.

01 / The Day

MONDAY 06 JUL 2026, ranked

Centenarians share a distinctive blood metabolite profile

Researchers at Boston University analysed plasma metabolomics across thousands of participants and found that individuals living past 100 display unusually elevated primary and secondary bile acids alongside preserved steroid levels. The pattern correlates with reduced mortality risk independently of other factors, suggesting these metabolic features are either directly protective or markers of underlying biology conferring extreme longevity.

Why it mattersA measurable metabolic fingerprint for exceptional longevity gives researchers a tractable target for biomarker development — grounded in the biochemistry of people who actually survived to 100, not animal models.

01 link.springer.com↗

Brain circuit linking deep sleep to growth hormone release identified

UC Berkeley researchers mapped a previously uncharacterised neural feedback loop connecting slow-wave sleep to pituitary growth hormone release. The circuit involves a specific interneuron population in the hypothalamus active only during deep sleep stages; disrupting it in animal models reduced growth hormone secretion by roughly half.

Why it mattersIdentifying the circuit rather than just observing the correlation makes the sleep-metabolism relationship mechanistically tractable — the pathway is now a target for interventions in metabolic decline, muscle repair, and potentially neurodegenerative conditions.

02 cell.com↗

First human trial of epigenetic reprogramming targets age-related blindness

Life Biosciences dosed the first patient in a Phase 1 clinical trial of an epigenetic reprogramming therapy aimed at reversing age-related optic nerve degeneration in glaucoma and optic neuropathy. The approach uses a partial reprogramming protocol intended to restore youthful gene expression patterns in retinal ganglion cells without inducing pluripotency.

Why it mattersMoving partial reprogramming from animal models into a human safety trial is a phase transition for the field — the next two years of Phase 1 data will substantially revise or reinforce confidence in the underlying biology.

03 lifebiosciences.com↗

Telomere damage signalling inhibition restores blood cell production in aged mice

Two companion studies in Nature Aging found that blocking the DNA damage response triggered by critically short telomeres in hematopoietic stem cells restored blood and immune cell production in aged mice toward youthful levels. The intervention did not require telomere lengthening — interrupting the damage signal alone was sufficient to re-activate quiescent stem cells.

Why it mattersDecoupling telomere length from telomere-driven stem cell dysfunction opens a therapeutic angle that sidesteps the safety concerns around lengthening telomeres in somatic tissue.

04 nature.com↗

TDP-43 conserved domain targeting slows ALS progression in mouse models

Nature Aging published results showing that therapeutic interference with a conserved region within TDP-43's low-complexity domain — the protein whose misfolding drives motor neuron death in most ALS cases — reduced neurodegeneration and extended survival in mouse models. The approach targets the domain driving misfolding, not aggregation after the fact.

Why it mattersALS has no disease-modifying treatment; a target within the most conserved part of the causative protein is mechanistically more tractable than aggregation-focused approaches that have not translated from animals to humans.

05 nature.com↗

Be subscriber #012 the weekly ten, every friday by email · no spam · unsubscribe anytime

Past days

The Daily Archive

/FRI 31 JULBlood proteins predict liver disease 16 years early /WED 29 JULWednesday, 29 July — Clocks, guts, heat /MON 27 JULFDA Splits the Peptide Vote, Salk Finds Zombie Cells' Weakness, and GBD Says Healthy Years Aren't Keeping Pace /FRI 24 JULThe Drug That Lost Its Heart /WED 22 JULBlood, bone, and the morbidity gap /FRI 17 JULFriday in Longevity: Clocks, Fat, and Immune Decay /WED 15 JULSenescent terrain /MON 13 JULLecanemab under the skin /FRI 10 JULLongevity | Jul 10 2026: Gut, Senescence, Epigenetics /WED 08 JULDrugs remapped to aging hallmarks, ovarian aging reversed, and a 50% molecular gap /MON 06 JULCentenarian chemistry, sleeping circuits, and reprogrammed eyes /FRI 03 JULOvaries, progenitors, and oxygen /WED 01 JULTelomere signals, proteomic clocks, and faster biological aging /MON 29 JUNMonday, June 29 — Longevity /FRI 26 JUNWhen you sleep matters; what your cells do with miscopied RNA also matters /TUE 23 JUNGenes, Clocks, and GLP-1s /MON 22 JUNMonday: Senescent cells, climbing clocks, and late-life gene therapy /FRI 19 JUNLongevity — June 19, 2026 /WED 17 JUNClocks, Loops, and One Very Productive Bacteria /MON 15 JUNReprogramming closes first human trial; circadian link firms /FRI 12 JUNAging regimes, borrowed sleep, and a race to measure biological age